MRF-Logo2019-Horizontal-RGB
Still waiting on call from BMS about Anti PD-1 but in the mean time I found this….
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Still waiting on call from BMS about Anti PD-1 but in the mean time I found this….

› Forums › General Melanoma Community › Still waiting on call from BMS about Anti PD-1 but in the mean time I found this….

  • This topic is empty.
  • Post
    • September 5, 2012 at 5:55 am
    LynnLuc
    Participant

      Based on the data, senior vice president of Global Development and Medical Affairs at Bristol-Myers Squibb Brian Daniels noted that the drugmaker "plan[s] to initiate registrational studies for anti-PD-1 in non-small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma." Leerink Swann analysts suggested that PD-1 inhibitors such as BMS-936558, which Bristol-Myers Squibb is developing with Ono Pharmaceutical, "could be the most exciting clinical and commercial opportunity in oncology,

      Based on the data, senior vice president of Global Development and Medical Affairs at Bristol-Myers Squibb Brian Daniels noted that the drugmaker "plan[s] to initiate registrational studies for anti-PD-1 in non-small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma." Leerink Swann analysts suggested that PD-1 inhibitors such as BMS-936558, which Bristol-Myers Squibb is developing with Ono Pharmaceutical, "could be the most exciting clinical and commercial opportunity in oncology," partly because such drugs might be able to treat a variety of cancers. Other companies developing compounds that work by similar mechanisms include GlaxoSmithKline, Merck & Co., Roche and Teva.

      http://www.firstwordplus.com/Fws.do?articleid=2A61789AB2FB4D9EBE51BD7CB230F954&src=corp_site

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics